The first results showed clinical benefit of nilotinib in some patients with melanoma harboring KIT alterations previously treated with KIT inhibitor (imatinib) but its efficacy in brain metastases was limited and needs further investigation (Table 3) [69]. This evidence concerns the gene KIT and melanoma.